NMBA Reversal and Postoperative Urinary Retention

Launched by BETH ISRAEL DEACONESS MEDICAL CENTER · Apr 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how different methods of reversing the effects of certain medications, called neuromuscular blocking agents (NMBAs), impact urinary problems after surgery. Specifically, it will compare two reversal methods: one using a medication called sugammadex and the other using neostigmine, which is combined with other medications to help with side effects. The study will also examine how these methods affect hospital costs and the need for unplanned visits back to the hospital.

To participate, you need to be an adult patient who is having non-urinary surgery under general anesthesia and has received either rocuronium or vecuronium for muscle relaxation during the procedure. You must also have your muscle relaxation reversed with either sugammadex or neostigmine. Participants will be monitored in the post-anesthesia care unit after their surgery. It's important to note that some patients will not be eligible, including those with serious health issues or certain urinary conditions. If you take part in this study, you'll help researchers understand how to improve care after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients
• • Non-urinary system surgery
• • General anesthesia
• • Use of rocuronium or vecuronium for neuromuscular blockade
• • Neuromuscular blockade reversal with sugammadex or neostigmine (with atropine and/or glycopyrrolate)
• • Postoperative admission to the post-anesthesia care unit (PACU)
• Exclusion Criteria:
• • American Society of Anesthesiologists (ASA) physical status ≥ V
• • Emergency reversal with sugammadex (≥ 16 mg/kg of sugammadex)
• • Presence of foley or suprapubic catheter before or after the procedure
• • Prior history of bladder resection surgery
• • Observations with missing data for pre-specified confounding variables